Skip to main content

Advertisement

SpringerLink
Log in

Deucravacitinib for Psoriasis

  • Psoriasis (J Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Deucravacitinib is an oral, selective TYK2 inhibitor that is currently in phase III of development for the treatment of psoriasis. This article reviews the mechanism and significance of TYK2 inhibition, as well as the current data on the safety and efficacy of deucravacitinib.

Recent Findings

Phase II results for deucravacitinib have shown that four out of six treatment groups resulted in statistically significant increases in PASI75 improvement over the placebo group. The most common adverse effects were headache, nasopharyngitis, upper respiratory tract infection, nausea, acne, and diarrhea. Three serious adverse events were noted in the treatment group, and they were gastroenteritis due to rotavirus, accidental eye injury, and dizziness.

Summary

Deucravacitinib holds great promise to meet the unfulfilled need for an efficacious oral small molecule treatment for psoriasis. However, phase III results will be needed to confirm the safety profile seen in phase I and phase II trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18–23 This paper is a good starting point for approaching psoriasis that, while a bit dated, represents a good historical summary of psoriasis before the age of biologics.

    Article  Google Scholar 

  2. Laws PM, Young HS. Current and emerging systemic treatment strategies for psoriasis. Drugs. 2012;72:1867–80.

    Article  CAS  Google Scholar 

  3. Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020;25:89–100.

    Article  CAS  Google Scholar 

  4. Bagel J, Gold LS. Combining topical psoriasis treatment to enhance systemic and phototherapy: a review of the literature. J Drugs Dermatol. 2017;16:1209–22.

    PubMed  Google Scholar 

  5. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–85.

    PubMed  PubMed Central  Google Scholar 

  6. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.

    Article  CAS  Google Scholar 

  7. Naldi L, Raho G. Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009;14:145–63.

    Article  CAS  Google Scholar 

  8. Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76:215–27.

    Article  CAS  Google Scholar 

  9. • Vangipuram R, Alikhan A. Apremilast for the management of moderate to severe plaque psoriasis. Expert Rev Clin Pharmacol. 2017;10:349–60 This manuscript outlines the data supporting the use of apremilast, the only targeted small molecule drug for psoriasis currently on the market, in treating psoriasis.

    Article  CAS  Google Scholar 

  10. Harrison DA. The /STAT pathway. Cold Spring Harb Perspect Biol. 2012. https://doi.org/10.1101/cshperspect.a011205.

  11. • Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194:21–7 This is an excellent manuscript summarizing the role of JAK/STAT signaling in multiple immune pathways leading to human disease processes.

    Article  CAS  Google Scholar 

  12. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–21.

    Article  CAS  Google Scholar 

  13. Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol BioSyst. 2006;2:536–50.

    Article  CAS  Google Scholar 

  14. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–87.

    Article  CAS  Google Scholar 

  15. Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745–55.

    Article  CAS  Google Scholar 

  16. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr. 2012;160:1055–7.

    Article  Google Scholar 

  17. • Kreins AY, Ciancanelli MJ, Okada S, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212:1641–62 This report shows the effects of TYK2 deficiency on people, illustrating the potential effects of blocking this pathway too strongly. While a small molecule drug would likely be able to stay within a therapeutic window to avoid these negative effects, it’s still important to recognize potential effects of inhibition of this pathway.

    Article  CAS  Google Scholar 

  18. Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8:363ra149.

    Article  Google Scholar 

  19. Boisson-Dupuis S, Ramirez-Alejo N, Li Z, Patin E, Rao G, Kerner G, et al. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant. Sci Immunol. 2018;3:eaau8714. https://doi.org/10.1126/sciimmunol.aau8714.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42:985–90.

    Article  Google Scholar 

  21. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–50.

    Article  Google Scholar 

  22. Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol. 2014;26:257–67.

    Article  CAS  Google Scholar 

  23. Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol. 2011;187:181–9.

    Article  CAS  Google Scholar 

  24. Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736.

    Article  Google Scholar 

  25. • Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019. https://doi.org/10.1021/acs.jmedchem.9b00444This paper outlines the development and basic properties of BMS-986165, now known as deucravacitinib.

  26. Catlett I, Aras U, Liu Y, Bei D, Girgis I, Murthy B, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Ann Rheum Dis. 2017;76:859.

    Google Scholar 

  27. • Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379:1313–21 This is the main study report of the phase 2 trial of deucravacitinib in treating psoriasis.

    Article  CAS  Google Scholar 

  28. Forman SB, Pariser DM, Poulin Y, Vincent MS, Gilbert SA, Kieras EM, et al. TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020;140:2359–2370.e5. https://doi.org/10.1016/j.jid.2020.03.962.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Dr. Jeffrey Weinberg for reviewing their manuscript.

Author information

Authors and Affiliations

  1. University of Illinois-Chicago College of Medicine, Chicago, IL, USA

    Lori S. Kim

  2. Dermatology Research and Education Foundation, Irvine, CA, USA

    Jashin J. Wu

  3. Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 E 98th St., Fifth Floor, Dermatology, New York, NY, 10029, USA

    George Han

Authors
  1. Lori S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jashin J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Han.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, L.S., Wu, J.J. & Han, G. Deucravacitinib for Psoriasis. Curr Derm Rep 10, 1–5 (2021). https://doi.org/10.1007/s13671-020-00326-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-020-00326-x

Keywords

Search

Navigation